Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 741

1.

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.

Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW.

J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034.

PMID:
19758616
2.

Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.

Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, Shariat SF, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS.

Urol Oncol. 2007 Jul-Aug;25(4):291-7.

PMID:
17628294
3.
4.

Impact of patient age on biochemical recurrence rates following radical prostatectomy.

Magheli A, Rais-Bahrami S, Humphreys EB, Peck HJ, Trock BJ, Gonzalgo ML.

J Urol. 2007 Nov;178(5):1933-7; discussion 1937-8.

PMID:
17868723
5.
6.

Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.

Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.

J Urol. 2006 Aug;176(2):554-8.

PMID:
16813888
7.

Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.

Caire AA, Sun L, Robertson CN, Polascik TJ, Maloney KE, George DJ, Price MM, Stackhouse DA, Lack BD, Albala DM, Moul JW.

Urology. 2010 May;75(5):1122-7. doi: 10.1016/j.urology.2009.06.091.

PMID:
19815259
8.

The impact of prostate gland weight in robot assisted laparoscopic radical prostatectomy.

Link BA, Nelson R, Josephson DY, Yoshida JS, Crocitto LE, Kawachi MH, Wilson TG.

J Urol. 2008 Sep;180(3):928-32. doi: 10.1016/j.juro.2008.05.029.

PMID:
18635217
9.

Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.

Smith CV, Bauer JJ, Connelly RR, Seay T, Kane C, Foley J, Thrasher JB, Kusuda L, Moul JW.

J Urol. 2000 Dec;164(6):1964-7.

PMID:
11061892
10.

Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.

Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.

J Urol. 2009 Nov;182(5):2250-5. doi: 10.1016/j.juro.2009.07.022.

PMID:
19758614
11.

Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.

Sengupta S, Christensen CM, Zincke H, Slezak JM, Leibovich BC, Bergstralh EJ, Myers RP, Blute ML.

J Urol. 2006 Aug;176(2):559-63.

PMID:
16813889
12.

Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.

Isariyawongse BK, Sun L, BaƱez LL, Robertson C, Polascik TJ, Maloney K, Donatucci C, Albala D, Mouraviev V, Madden JF, Moul JW.

Urology. 2008 Oct;72(4):882-6. doi: 10.1016/j.urology.2008.02.021.

PMID:
18384857
13.

Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?

Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ.

J Urol. 2007 Jan;177(1):102-6; discussion 106.

PMID:
17162013
14.

Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.

Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML.

BJU Int. 2008 Feb;101(3):299-304.

15.

Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.

Buschemeyer WC 3rd, Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ.

J Urol. 2008 Jan;179(1):124-9; discussion 129.

PMID:
17997433
16.

Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?

Caire AA, Sun L, Ode O, Stackhouse DA, Maloney K, Donatucci C, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW.

Urology. 2009 Sep;74(3):643-7. doi: 10.1016/j.urology.2009.02.049.

PMID:
19501891
17.

The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.

Pruthi RS, Swords K, Schultz H, Carson CC 3rd, Wallen EM.

J Urol. 2009 Feb;181(2):574-7; discussion 578. doi: 10.1016/j.juro.2008.10.028.

PMID:
19084847
18.

Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.

Loeb S, Nadler RB, Roehl KA, Antenor JA, Catalona WJ.

J Urol. 2007 May;177(5):1745-8.

PMID:
17437803
19.

Changing nature of high risk patients undergoing radical prostatectomy.

Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Freedland SJ; SEARCH Database Study Group..

J Urol. 2007 Jan;177(1):113-7.

PMID:
17162017
20.

Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival in patients with seminal vesicle invasion after radical prostatectomy.

Secin FP, Bianco FJ Jr, Vickers AJ, Reuter V, Wheeler T, Fearn PA, Eastham JA, Scardino PT.

Cancer. 2006 Jun 1;106(11):2369-75.

Items per page

Supplemental Content

Support Center